Erythropoietin Molecules to Treat Acute Ischemic Stroke: A Translational Dilemna!

摘要

Importance of the fieldSince the realization that Erythropoietin (EPO) molecules have “neuroprotective” properties, they have been investigated as treatments for acute ischemic stroke (AIS), but not systematically. The results of the 2009 clinical trial showed that EPO was ineffective as a stroke treatment, and moreover, increased mortality when combined with tissue plasminogen activator (tPA). Currently, CEPO, an EPO analog is entering into a safety, tolerability and pharmacokinetic clinical trial for the treatment of AIS.